Induction ofStaphylococcus aureus-specific IgA and agglutination potency in milk of cows by mucosal immunization

Lactating cows were immunized with inactivatedStaphylococcus aureusstrains and concentrated culture supernatants. Application of a repeated mucosal immunization scheme resulted in significant levels ofS. aureus-specific IgA in milk of dairy cows. Average IgA titers against whole cellS. aureusincreas...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine Vol. 27; no. 30; p. 4001
Main Authors: Tempelmans Plat-Sinnige, Marjan J, Verkaik, Nelianne J, van Wamel, Willem JB, de Groot, Nanda, Acton, Dennis S, van Belkum, Alex
Format: Journal Article
Language:English
Published: Kidlington Elsevier Limited 19-06-2009
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Lactating cows were immunized with inactivatedStaphylococcus aureusstrains and concentrated culture supernatants. Application of a repeated mucosal immunization scheme resulted in significant levels ofS. aureus-specific IgA in milk of dairy cows. Average IgA titers against whole cellS. aureusincreased during the first 10 weeks of immunization after which a plateau level was reached and maintained during lactation. Immune whey agglutinated both bovine and humanS. aureusstrains including methicillin-resistantS. aureus(MRSA) strains and recognized extractedS. aureusproteins on Western blot. ELISAs to quantify milk IgA reactive with a number ofS. aureusvirulence proteins (e.g. enterotoxins, microbial surface component recognizing adhesive matrix molecules (MSCRAMMs) and immune modulating proteins) and cell wall components, demonstrated the polyclonality of the IgA. Correlations observed between agglutination and specific IgA titers for whey and for purified IgA suggested functionality of the induced antibodies. Milk from immunized cows may provide a way of producing potentially therapeutic polyclonal antibodies againstS. aureuscolonization and infection.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2009.04.034